BioSpace News Archive

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced its commitment to improving outcomes for patients with prostate cancer through its participation in the Hampton University Proton Therapy Institute Prostate Cancer & Men’s Health Fair.

Curiox Biosystems is pleased to announce its collaboration with Dr. Marco Ruella, an Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn), to support efforts in the development of next-generation cancer cell therapies.

AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease, announced that it intends to offer to sell its ordinary shares in an underwritten public offering.

Caliway Biopharmaceuticals announced that all the primary and secondary efficacy endpoints were met in the analysis of the ITT population and PP population from the CBL-0201DD Phase 2 study, evaluating CBL-514’s efficacy and safety on participants with Dercum’s Disease lipomas.

J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held in Singapore from 9th to 12th September, during the official session entitled “Metastatic Non-small Cell Lung Cancer – Targeted Therapy - EGFR/HER2".

Immuron Limited is pleased to announce record monthly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Aurora Spine Corporation announced today that it is in full commercial release of its proprietary SiLO TFX™ MIS Sacroiliac Joint Fixation Device system.

iSpecimen Inc. announced today that the Company has recently expanded its global provider network to help advance women’s health research.